← Evidence map

ArticleTargeted oncology2025

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.

Jean Mourlanette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study. | OpenQuestion